Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

42 citing papers in PubMed.

1. Zalunfiban at First Medical Contact for ST-Elevation Myocardial Infarction.NEJM evidence · 2026
   Trial
2. Emerging Targets, Novel Directions, and Innovative Approaches in Thrombosis Therapy.Aging and disease · 2025
   Review
3. Application of Funnel Metadynamics to the Platelet Integrin αIIbβ3 in Complex with an RGD Peptide.International journal of molecular sciences · 2024
   Article
4. Molecular mechanisms of catch bonds and their implications for platelet hemostasis.Biophysical reviews · 2023
   Review
5. Influence of integrins on thrombus formation: a road leading to the unravelling of DVT.Molecular and cellular biochemistry · 2021
   Review
6. Direct Fibrinolytic Snake Venom Metalloproteinases Affecting Hemostasis: Structural, Biochemical Features and Therapeutic Potential.Toxins · 2017
   Review
7. Abciximab-induced acute profound thrombocytopenia postpercutaneous coronary intervention.BMJ case reports · 2017
   Article
8. Abciximab-induced delayed profound thrombocytopaenia.BMJ case reports · 2017
   Article
9. Integrin-based therapeutics: biological basis, clinical use and new drugs.Nature reviews. Drug discovery · 2016
   Review
10. A Novel Model of Intravital Platelet Imaging Using CD41-ZsGreen1 Transgenic Rats.PloS one · 2016
    Article
11. [Antiplatelet therapy in acute coronary syndrome. Prehospital phase: nothing, aspirin or what?].Herz · 2014
    Article
12. Evolution and medicine in undergraduate education: a prescription for all biology students.Evolution; international journal of organic evolution · 2012
    Article
13. Enhancing the Teaching of Evolution in Public Health.Evolution · 2011
    Article
14. Historical perspective and future directions in platelet research.Journal of thrombosis and haemostasis : JTH · 2011
    Review
15. Association of the platelet GPIIb/IIIa polymorphism with atherosclerotic plaque morphology: the Atherosclerosis Risk in Communities (ARIC) Study.Atherosclerosis · 2011
    Article
16. The human endogenous circadian system causes greatest platelet activation during the biological morning independent of behaviors.PloS one · 2011
    Article
17. Anucleate platelets generate progeny.Blood · 2010
    Article
18. Pathogenic hantaviruses direct the adherence of quiescent platelets to infected endothelial cells.Journal of virology · 2010
    Article
19. The final steps of integrin activation: the end game.Nature reviews. Molecular cell biology · 2010
    Review
20. Antiplatelet therapies for the treatment of cardiovascular disease.Nature reviews. Drug discovery · 2010
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as